Calmare Therapeutics — Competitive Technologies — Investor Presentation (May 2014)
26 slides from Calmare Therapeutics's investor presentation, May 28, 2014
Slide 1: Investor Presentation First Quarter 2014
Investor Presentation FIRST QUARTER 2014 Unlocking the Potential of Innovation © 2014 Competitive Technologies, Inc
Slide 2: Forward-Looking Statements
THIS PRESENTATION CONTAINS “FORWARD - LOOKING STATEMENTS” WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. SUCH FORWARD - LOOKING STATEMENTS INVOLVE KNOWN AND UNKNOWN RISKS, UNCERTAINTIES AND OTHER FACTORS WHICH MAY CAUSE THE ACTUAL RESULTS, PERFORMANCE OR ACHIEVEMENTS OF
Slide 3: Our Company
Unlocking the Potential of Innovation Our Company
Slide 4: Biotechnology company focused on pain management
is a biotechnology company that develops and commercializes innovative medical products and technologies with a concentration in pain management. • Established in 1968 and headquartered in Fairfield, CT • Publicly traded on the OTCQX | ticker symbol “CTTC” © 2014 Competitive Technologies, Inc
Slide 5: Dr. David Borsook on lack of effective chronic pain treatments
Dr. David Borsook, MD. PhD Director of Pain, Children’s Hospital Mass General Hospital, Boston. Mass . “ We do not yet have medications or other treatments that can effectively alleviate chronic pain with speed or efficiency in the majority of patients. Doctors treat patients with a trial - and - er
Slide 6: Prescription painkiller overdoses killed over 6,000 people in the US in 2010
© 2014 Competitive Technologies, Inc Prescription painkiller overdoses killed nearly over 6,000 people in the US in 2010.
Slide 7: © 2014 Competitive Technologies, Inc
© 2014 Competitive Technologies, Inc
Slide 8: Pain Device
Unlocking the Potential of Innovation Pain Device
Slide 9: Proprietary non-invasive pain medical device
© 2014 Competitive Technologies, Inc Our proprietary, patented, non - invasive medical device developed to treat high intensity oncologic and neuropathic pain without the harmful side effects of narcotic painkillers. • Immediate to prolonged pain relief • Procedure regimen : — 10 to 15 treatments ov
Slide 10: How the device scrambles the pain signal
© 2014 Competitive Technologies, Inc 1. Certified practitioners place surface electrodes on the patient’s skin close to the pain source in order to access their C - fiber 2. Our patented multi - processor sends an algorithmically - scrambled pain message to the brain along the patient’s C - fibers a
Slide 11: Pain indications treated
© 2014 Competitive Technologies, Inc • Chemotherapy - Induced Peripheral Neuropathy (CIPN) • Chronic Regional Pain Syndrome (CRIP) • Failed Back Surgery Syndrome • Chronic Post - Herpetic Neuralgia (PHN) • Sciatic and Lumbar Pain • Low Back Pain (LBP) • Post - Surgical Pain • Brachial Plexus Pain •
Slide 12: Global pain management market and target patients
© 2014 Competitive Technologies, Inc $ 28 . 6 billion : Global pain management therapeutic market (CAGR of 5 . 3 % between 2002 and 2010 ) 116 million : Amount of U . S . adults that experience chronic pain daily 15 million : Amount U . S . adults that suffer from neuropathic pain* CTI is targeting
Slide 13: Terminal cancer patients pain reduction
© 2014 Competitive Technologies, Inc • 33 Terminal cancer patients suffering from severe drug resistant and were treated with Calmare . Chart shows pain reduction after each treatment during 10 sessions. The pain was reduced to zero. Marineo G et al International Congress Series 1255(203) 381 - 388
Slide 14: Calmare versus drug control group
© 2014 Competitive Technologies, Inc • Comparison of pain reduction between drugs (control group) and one treated with Calmare (26/Drug – 26/ST) • 72 % of patients drug and pain free • 20 % of remaining patients on reduced drug dosages after Calmare treatment G.Marineo , T. Smith, et al, JPSM 2011
Slide 15: CIPN pain score reduction
© 2014 Competitive Technologies, Inc • Calmare helps drug refractory CIPN patients overall pain score reduction by 64% Smith T. et al Journal of Pain And Symptom Management 2010
Slide 16: Clinical institution findings
© 2014 Competitive Technologies, Inc • Mayo Clinic: Charles Loprinzi, MD ( Third Annual Cancer Pain Conference) − Calmare creates "non pain" information in packets of rapidly varying impulses, given non - invasively using the patients’ own nerves − (Calmare) therapy looks very promising in 3 pilot t
Slide 17: Device market opportunity
© 2014 Competitive Technologies, Inc Each patient: 12 treatments over 2 weeks Each Calmare device: 6 patients / 2 weeks = 156 patients per year 5 % summary: 5.8 million patients /156 patients = 37 , 000 Devices 37,000 devices @ $105,000 $3.89 B Market 37,000 devices @ $75,000 $2.78 B Gross Profit
Slide 18: Practice economics per patient
© 2014 Competitive Technologies, Inc Each New Patient : 12 treatments over 2 weeks Primary Treatment Cost: $250 per patient = $3,000 1 over 2 weeks (est.) Practice Income (per month): 12 patients $ 36,000 Product Leasing: $ 1,900 2 Monthly Profit: $ 34,100 1 Average per patient cost Nationwide. 2 5%
Slide 19: Market opportunity versus Medtronic
© 2014 Competitive Technologies, Inc Each patient: 12 treatments over 2 weeks Each Calmare device: 6 patients / 2 weeks = 156 patients per year 5% summary: 5.8 million patients /156 patients = 37 , 000 Devices 37,000 devices @ $105,000 $3.89 B Market 37,000 devices @ $75,000 $2.78 B Gross Profit Med
Slide 20: Investment Opportunity
Unlocking the Potential of Innovation Investment Opportunity
Slide 21: Sales, certification and pivotal trial plan
© 2014 Competitive Technologies, Inc P roduct sales : − U.S.: Nurse/Sales person tandem − Europe, Middle East, No. Africa: distributor sales − Military: b lanket p urchase agreement Certification program: − Practitioner certification − Continued education fees C onduct Pivotal trial: − Multi - cente
Slide 22: Seeking $5.0 million investment in two tranches
© 2014 Competitive Technologies, Inc CTI is seeking a total investment of $5.0 million in two tranches : $ 1.5 million in Tranche One already raised $1.2 million $ 3.5 million in Tranche Two — Use of Funds: o Clinical trial costs (pivotal) o Personnel: CMO and International Sales Executive o General
Slide 23: Recent accomplishments
© 2014 Competitive Technologies, Inc x Repaid Tonaquint Note x Reestablished EMENA territory x Key Hires: • CFO • US Sales • Product Marketing x Reduce expenses x Streamline product sales
Slide 24: Stock and capitalization data
© 2014 Competitive Technologies, Inc Stock Price ( 5 / 23 / 14 ) …… . …………… . ………… .. $ 0 . 42 52 - week Hi - Lo ……………… .. ……… . …… $ 0 . 05 - $ 0 . 55 Ave . Daily Trading Vol . ( 3 m) … .. …………… .. … ... 25 , 309 Market Cap ( 5 / 23 / 14 ) … .. ………… .. … ... … .. $ 9 . 4 million Shares Outstanding
Slide 25: Board of directors
© 2014 Competitive Technologies, Inc Peter Brennan, Chairman – As Chairman and the largest shareholder of the company Mr. Brennan brings financial and governance leadership to the company. He spent the last 30 years working in the investment management business and is the founder of Damel Investment
Slide 26: Thank you
Thank you! Unlocking the Potential of Innovation © 2014 Competitive Technologies, Inc Conrad Mir President & CEO 973.798.8882 Direct cmir@competitivetech.com www.competitivetech.net
Competitive Technologies — Investor Presentation (May 2014) on 6ix